AVBP – arrivent biopharma, inc. (US:NASDAQ)
Stock Stats
News
ArriVent BioPharma (AVBP) was upgraded by Truist Financial Corporation to "strong-buy".
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib [Seeking Alpha]
ArriVent BioPharma (AVBP) had its price target raised by B. Riley Financial, Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting [Yahoo! Finance]
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 [Yahoo! Finance]
Form 8-K ArriVent BioPharma, Inc. For: Mar 17
Form S-8 ArriVent BioPharma, Inc.
Form 10-K ArriVent BioPharma, Inc. For: Dec 31
Form 8-K ArriVent BioPharma, Inc. For: Mar 05
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: Sofinnova Venture Partners IX, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.